GAITHERSBURG, Md., Sept. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, will be interviewed at Devex @ UNGA
Interview details are as follows:
For more information or to register for the fireside chat, visit:https://pages.devex.com/devex-at-unga-76.html
About NovavaxNovavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts: InvestorsNovavax, Inc.Erika Schultz | Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
Solebury TroutAlexandra Roy | Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
MediaAlison Chartan | 240-720-7804Laura Keenan | Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
Logo - https://mma.prnewswire.com/media/1506866/Novavax_High_Res_Logo.jpg
